» Articles » PMID: 36999101

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy

Overview
Journal Cureus
Date 2023 Mar 31
PMID 36999101
Authors
Affiliations
Soon will be listed here.
Abstract

Cytomegalovirus (CMV) is a human herpes-type virus with variable clinical manifestations. Infections in immunocompetent patients are usually asymptomatic or mild, and severe infections are generally seen in immunosuppressed individuals. CMV colitis is not uncommon in patients with ulcerative colitis (UC) and is mostly associated with the use of steroids, immunomodulators like azathioprine, and biologics like infliximab, which have systemic immunosuppressive effects. Vedolizumab is an anti-integrin antibody that is gut-selective without any systemic effects. We report an unusual presentation of a female patient with UC who had concomitant CMV colitis and erythema nodosum, who was on vedolizumab, and not on any steroids or other immunosuppressants. She responded well to anti-viral treatment and steroids.

Citing Articles

A diagnostic dilemma: cytomegalovirus colitis as an uncommon comorbidity in inflammatory bowel disease: a case report.

Alhalabi M, Alziadan S Virol J. 2024; 21(1):188.

PMID: 39152468 PMC: 11330031. DOI: 10.1186/s12985-024-02467-y.


Cytomegalovirus Infection in Adult Patients with Inflammatory Bowel Disease: A Literature Review.

Momayaz Sanat Z, Siami Z, Alatab S, Vahedi H, Fanni Z Arch Iran Med. 2024; 27(5):277-286.

PMID: 38690795 PMC: 11097322. DOI: 10.34172/aim.2024.40.


Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis.

Bao M, Kennedy J, Dolinger M, Dunkin D, Lai J, Dubinsky M Crohns Colitis 360. 2024; 6(1):otae014.

PMID: 38444641 PMC: 10914341. DOI: 10.1093/crocol/otae014.

References
1.
Vega R, Bertran X, Menacho M, Domenech E, de Vega V, Hombrados M . Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 1999; 94(4):1053-6. DOI: 10.1111/j.1572-0241.1999.01013.x. View

2.
Colombel J, Sands B, Rutgeerts P, Sandborn W, Danese S, DHaens G . The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016; 66(5):839-851. PMC: 5531223. DOI: 10.1136/gutjnl-2015-311079. View

3.
Romkens T, Bulte G, Nissen L, Drenth J . Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol. 2016; 22(3):1321-30. PMC: 4716042. DOI: 10.3748/wjg.v22.i3.1321. View

4.
Cannon M, Schmid D, Hyde T . Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010; 20(4):202-13. DOI: 10.1002/rmv.655. View

5.
Wyant T, Fedyk E, Abhyankar B . An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. J Crohns Colitis. 2016; 10(12):1437-1444. DOI: 10.1093/ecco-jcc/jjw092. View